Bristol-Myers Squibb Competitive Strategy & Market Position
BMS's advantage is its expertise in oncology and its large commercial and regulatory organization. Developing a cancer immunotherapy is complex, and winning approval from regulators and getting doctors to prescribe it requires an established global sales and regulatory team. Smaller biotech companies often lack that infrastructure, so they partner with or sell to a company like BMS to bring their discoveries to market.
- What is Bristol-Myers Squibb's competitive advantage?
- BMS's advantage is its expertise in oncology and its large commercial and regulatory organization.
- Who are Bristol-Myers Squibb's competitors?
- Bristol-Myers Squibb's main competitors covered here are Pfizer, Merck and Johnson & Johnson.
- What is Bristol-Myers Squibb's market share?
- Eliquis is the best-selling oral anticoagulant worldwide, with $14.4 billion of BMS-reported sales in 2025. Opdivo is the second-largest PD-1 inhibitor behind Merck's Keytruda. In multiple myeloma BMS still sells Revlimid and Pomalyst but is losing share to generics and to CAR-T and bispecific therapies from rivals. About 69 percent of BMS's 2025 revenue came from the United States.
Core Strength
Eliquis ($14.4 billion) and Opdivo ($10.0 billion) produced about half of 2025 revenue and help fund roughly $12.8 billion of annual free cash flow, a dividend raised 17 years running and continued deal-making.
Key Weakness
Eliquis and Opdivo both lose U.S. exclusivity in 2028, and Revlimid, Pomalyst and Sprycel are already losing sales to generics. Revlimid alone fell from $12.8 billion in 2021 to $3.0 billion in 2025.
Market Position & Competitive Landscape
BMS faces a different rival in almost every therapy area. In immuno-oncology, Opdivo ($10.0 billion in 2025) trails Merck's Keytruda, which pulled ahead after BMS's CheckMate-026 trial failed in first-line lung cancer in 2016; BMS has answered with combinations (Opdivo plus Yervoy, and Opdualag, which adds the LAG-3 antibody relatlimab) and the subcutaneous Opdivo Qvantig. In anticoagulation, Eliquis competes with Xarelto from Bayer and Johnson & Johnson, and BMS and J&J are co-developing the factor XIa drug milvexian as a possible successor. In multiple myeloma, Revlimid and Pomalyst face generics while CAR-T and bispecific antibodies take share; BMS's own cell therapies Breyanzi and Abecma compete with Gilead's Kite and with Carvykti from J&J and Legend Biotech. In psoriasis, Sotyktu competes with Amgen's Otezla, the drug Celgene had to sell to get the BMS merger approved. Cobenfy, the first schizophrenia drug that acts on muscarinic rather than dopamine receptors, competes mainly with low-cost generic antipsychotics. In PD-(L)1 x VEGF bispecific antibodies, the BioNTech-partnered BNT327 is racing Summit Therapeutics and Akeso's ivonescimab.
Key Competitors
| Competitor | Profile |
|---|---|
| Pfizer | View Profile → |
| Merck | View Profile → |
| Johnson & Johnson | View Profile → |
Bristol-Myers Squibb Competitors, SWOT and Strategy FAQ
What is Bristol-Myers Squibb's overarching competitive biopharma strategy?
BMS pursues a 'Diversified Specialty Biopharma' strategy, targeting high-unmet-need diseases across oncology, cardiology, immunology, and neuroscience where breakthrough science can command premium pricing, long patent protection, and high clinical standard-of-care adoption.
How did Opdualag establish a new standard of care in melanoma?
Opdualag combines PD-1 inhibitor nivolumab with relatlimab, a first-in-class LAG-3 immune checkpoint inhibitor, simultaneously blocking two complementary inhibitory pathways to double progression-free survival in advanced melanoma compared to single-agent PD-1 therapy.
What is BMS's clinical positioning with Sotyktu in autoimmune psoriasis?
Sotyktu (deucravacitinib) is the first and only selective, allosteric oral TYK2 inhibitor approved for moderate-to-severe plaque psoriasis, delivering superior skin clearance to legacy oral treatments (Otezla) without the broad black-box warnings of standard JAK inhibitors.
How is BMS building a radiopharmaceutical business through RayzeBio?
BMS completed the $4.1 billion RayzeBio purchase ($62.50 per share) in February 2024. RayzeBio's lead program, RYZ101, uses the alpha-emitting isotope actinium-225 to target SSTR2-positive neuroendocrine tumors, and the deal included isotope manufacturing capacity.
What is BMS's targeted oncology strategy following the Mirati Therapeutics acquisition?
BMS completed the Mirati deal in January 2024 for $4.8 billion in cash plus a contingent value right worth up to $1 billion, adding Krazati (adagrasib), an approved KRAS G12C inhibitor for lung and colorectal cancer that sold $205 million in 2025, plus earlier KRAS programs.
How does BMS compete in CAR-T cell therapy?
BMS sells two CAR-T therapies made from each patient's own T cells: Breyanzi for lymphomas and other B-cell cancers, which sold $1.4 billion in 2025, and Abecma for multiple myeloma, which sold $427 million as Carvykti from Johnson & Johnson and Legend Biotech took share. It partnered with Cellares in 2023 on automated manufacturing and bought Orbital Therapeutics in 2025 to work on CAR-T made inside the body.
How does the Inflation Reduction Act affect BMS?
Eliquis was among the first ten drugs selected for Medicare price negotiation in August 2023, and its negotiated price took effect on January 1, 2026. BMS sued to block the program in 2023 and has leaned on newer brands such as Camzyos, Cobenfy and the subcutaneous Opdivo Qvantig for growth.
How does BMS engage in strategic external academic and biotech collaborations?
BMS forms early-stage discovery alliances with premier research institutes (Dana-Farber, Memorial Sloan Kettering) and biotechs, utilizing targeted protein degradation (molecular glues) and AI-driven computational biology to design next-generation drug candidates.
What is BMS's competitive advantage?
Its absolute moat is its early, massive dominance in immuno-oncology (drugs like Opdivo that train the immune system to fight cancer), and its sheer financial scale to simply buy out promising biotech startups.